Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

264 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.
Oxenius A, Price DA, Günthard HF, Dawson SJ, Fagard C, Perrin L, Fischer M, Weber R, Plana M, García F, Hirschel B, McLean A, Phillips RE. Oxenius A, et al. Among authors: phillips re. Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13747-52. doi: 10.1073/pnas.202372199. Epub 2002 Oct 7. Proc Natl Acad Sci U S A. 2002. PMID: 12370434 Free PMC article. Clinical Trial.
Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy.
Oxenius A, McLean AR, Fischer M, Price DA, Dawson SJ, Hafner R, Schneider C, Joller H, Hirschel B, Phillips RE, Weber R, Günthard HF; Swiss HIV Cohort Study Group. Oxenius A, et al. Among authors: phillips re. J Virol. 2002 Oct;76(20):10169-76. doi: 10.1128/jvi.76.20.10169-10176.2002. J Virol. 2002. PMID: 12239291 Free PMC article.
Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.
Price DA, Scullard G, Oxenius A, Braganza R, Beddows SA, Kazmi S, Clarke JR, Johnson GE, Weber JN, Phillips RE. Price DA, et al. Among authors: phillips re. J Virol. 2003 May;77(10):6041-9. doi: 10.1128/jvi.77.10.6041-6049.2003. J Virol. 2003. PMID: 12719595 Free PMC article. Clinical Trial.
Loss of viral control in early HIV-1 infection is temporally associated with sequential escape from CD8+ T cell responses and decrease in HIV-1-specific CD4+ and CD8+ T cell frequencies.
Oxenius A, Price DA, Trkola A, Edwards C, Gostick E, Zhang HT, Easterbrook PJ, Tun T, Johnson A, Waters A, Holmes EC, Phillips RE. Oxenius A, et al. Among authors: phillips re. J Infect Dis. 2004 Aug 15;190(4):713-21. doi: 10.1086/422760. Epub 2004 Jul 20. J Infect Dis. 2004. PMID: 15272399
Quantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDS.
Scherer A, Frater J, Oxenius A, Agudelo J, Price DA, Günthard HF, Barnardo M, Perrin L, Hirschel B, Phillips RE, McLean AR; Swiss HIV Cohort Study. Scherer A, et al. Among authors: phillips re. Proc Natl Acad Sci U S A. 2004 Aug 17;101(33):12266-70. doi: 10.1073/pnas.0404091101. Epub 2004 Aug 9. Proc Natl Acad Sci U S A. 2004. PMID: 15302942 Free PMC article.
Direct ex vivo analysis reveals distinct phenotypic patterns of HIV-specific CD8(+) T lymphocyte activation in response to therapeutic manipulation of virus load.
Oxenius A, Günthard HF, Hirschel B, Fidler S, Weber JN, Easterbrook PJ, Bell JI, Phillips RE, Price DA. Oxenius A, et al. Among authors: phillips re. Eur J Immunol. 2001 Apr;31(4):1115-21. doi: 10.1002/1521-4141(200104)31:4<1115::aid-immu1115>3.0.co;2-9. Eur J Immunol. 2001. PMID: 11298336 Free article.
264 results